476
Views
10
CrossRef citations to date
0
Altmetric
Drug Evaluation

Ipragliflozin, a sodium–glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes

, MD MBA (Instructor in Medicine) & , MBBS FRCP FACP (Theodore E. Woodward Professor of Medicine, Chairman, Physician-in-Chief)

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (4)

Weiping Chen, Pengyun Li, Guoqi Wang, Yang Chen, Bin Wang & Mulan Chen. (2019) Efficacy and safety of ipragliflozin as add-on to metformin for type 2 diabetes: a meta-analysis of double-blind randomized controlled trials. Postgraduate Medicine 131:8, pages 578-588.
Read now
Brian Tomlinson, Miao Hu, Yuzhen Zhang, Paul Chan & Zhong-Min Liu. (2017) Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology 13:2, pages 211-223.
Read now
Avivit Cahn, Simona Cernea & Itamar Raz. (2016) An update on DPP-4 inhibitors in the management of type 2 diabetes. Expert Opinion on Emerging Drugs 21:4, pages 409-419.
Read now
Maka S Hedrington & Stephen N Davis. (2015) The role of empagliflozin in the management of type 2 diabetes by patient profile. Therapeutics and Clinical Risk Management 11, pages 739-749.
Read now

Articles from other publishers (6)

Jonali Ramani, Harshil Shah, Vivek K. Vyas & Manmohan Sharma. (2022) A review on the medicinal chemistry of sodium glucose co-transporter 2 inhibitors (SGLT2-I): Update from 2010 to present. European Journal of Medicinal Chemistry Reports 6, pages 100074.
Crossref
Reyhaneh Moradi‐Marjaneh, Maryam Paseban & Amirhossein Sahebkar. (2019) Natural products with SGLT2 inhibitory activity: Possibilities of application for the treatment of diabetes. Phytotherapy Research 33:10, pages 2518-2530.
Crossref
Shuai Ma, Zhenren Liu, Jing Pan, Shunli Zhang & Weicheng Zhou. (2017) A concise and practical stereoselective synthesis of ipragliflozin L-proline. Beilstein Journal of Organic Chemistry 13, pages 1064-1070.
Crossref
Kyung-Wan MinBon Jeong KuJi-Hyun LeeMin-Seon KimKyu-Jeung AhnMoon-Kyu LeeSatoshi KokuboSatoshi YoshidaHyun-Ji ChoBong-Soo Cha. (2017) Addition of Ipragliflozin to Metformin Treatment in Korean Patients with Type 2 Diabetes Mellitus: Subgroup Analysis of a Phase 3 Trial. Diabetes & Metabolism Journal 41:2, pages 135.
Crossref
Eiji Kutoh, Teruma Murayama, Asuka Wada & Mitsuru Hirate. (2016) Distinct Glucose-Lowering Mechanisms of Ipragliflozin Depending on Body Weight Changes. Drugs in R&D 16:4, pages 369-376.
Crossref
DAVID CALDERÓN GUZMÁN, HUGO JUÁREZ OLGUÍN, ERNESTINA HERNÁNDEZ GARCÍA, MARIBEL ORTIZ HERRERA & NORMA OSNAYA BRIZUELA. (2016) Moieties in antidiabetic drugs as a target of insulin receptors in association with common neurological disorders. Biomedical Reports 4:4, pages 395-399.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.